SANA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.140

-33.38%

-0.137

-34.92%

-0.142

-63.67%

Estimates Revision

Stock Price

Go Up

+4.95%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

7.00

High

9.00

Current: 0.000

Low

5.00

Averages

7.00

High

9.00

BofA

Buy

maintain

$6 -> $7

2026-01-06

New

Reason

BofA

Price Target

$6 -> $7

2026-01-06

New

maintain

Buy

Reason

BofA raised the firm's price target on Sana Biotechnology to $7 from $6 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Citizens JMP

Outperform

maintain

$5 -> $8

2025-10-30

Reason

Citizens JMP

Price Target

$5 -> $8

2025-10-30

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Sana Biotechnology to $8 from $5 and keeps an Outperform rating on the shares. Sana's enhanced Fusogen platform now offers improved specificity and expansion, with an IND filing anticipated in 2026, the analyst tells investors in a research note. Progress across multiple programs, including the modified pancreatic islet cell IST in T1D, the iPSC program nearing IND readiness, and SC291 data expected in 4Q25, combined with a $177.2M pro forma cash position, suggests the shares remain undervalued with potential upside from future Fusogen monetization, Citizens says.

Wedbush

NULL -> Outperform

initiated

2025-09-24

Reason

Wedbush

Price Target

2025-09-24

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Sana Biotechnology with an Outperform rating and $5 price target.

Wedbush

Outperform

initiated

2025-09-24

Reason

Wedbush

Price Target

2025-09-24

initiated

Outperform

Reason

As previously reported, Wedbush initiated coverage of Sana Biotechnology with an Outperform rating and $5 price target. Lead candidate SC451 is an off-the-shelf pancreatic islet cell therapy for type 1 diabetes, which can address the limitations of device-based management and islet cell transplant. A second program, SG299, is an in vivo CART cell therapy candidate which may address the hurdles of cost, lymphodepletion, and access associated with current autologous CAR-T approaches. Both programs may enter the clinic as early as 2026, the firm notes. Wedbush views Sana as holding scarcity value for both its immune evasion and in vivo CART platforms, with substantial long-term growth potential.

Morgan Stanley

Maxwell Skor

Overweight

initiated

$12

2025-07-02

Reason

Morgan Stanley

Maxwell Skor

Price Target

$12

2025-07-02

initiated

Overweight

Reason

Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology with an Overweight rating and $12 price target. Six-month data for UP421 in type 1 diabetes show continued cell survival and insulin production without immunosuppression, notes the analyst, who looks forward to an investigational new drug filing for the company's proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451, as early as next year.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$11

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$11

2025-03-18

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Sana Biotechnology Inc (SANA.O) is -7.46, compared to its 5-year average forward P/E of -5.29. For a more detailed relative valuation and DCF analysis to assess Sana Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.29

Current PE

-7.46

Overvalued PE

-1.88

Undervalued PE

-8.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.51

Current EV/EBITDA

-6.17

Overvalued EV/EBITDA

-0.60

Undervalued EV/EBITDA

-8.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SANA News & Events

Events Timeline

No data

News

1.0

01-07Globenewswire

Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference

3.5

2025-12-08Globenewswire

Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology

3.5

2025-12-08Newsfilter

Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology

People Also Watch

Frequently Asked Questions

What is Sana Biotechnology Inc (SANA) stock price today?

The current price of SANA is 4.56 USD — it has increased 0.88 % in the last trading day.

What is Sana Biotechnology Inc (SANA)'s business?

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

What is the price predicton of SANA Stock?

What is Sana Biotechnology Inc (SANA)'s revenue for the last quarter?

Sana Biotechnology Inc revenue for the last quarter amounts to -40.39M USD, decreased -39.95 % YoY.

What is Sana Biotechnology Inc (SANA)'s earnings per share (EPS) for the last quarter?

Sana Biotechnology Inc. EPS for the last quarter amounts to -29470000.00 USD, decreased -47.29 % YoY.

What changes have occurred in the market's expectations for Sana Biotechnology Inc (SANA)'s fundamentals?

The market is revising No Change the revenue expectations for SANA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 4.95%.

How many employees does Sana Biotechnology Inc (SANA). have?

Sana Biotechnology Inc (SANA) has 194 emplpoyees as of January 11 2026.

What is Sana Biotechnology Inc (SANA) market cap?

Today SANA has the market capitalization of 1.21B USD.